Answers are grounded in this paper and cite their sources.
Sir, A large number of acquired carbapenemases have been identified and characterized among Gram-negative pathogens. These diverse enzymes, belonging to either molecular classes A and D (serine carbapenemases and oxacillinases) or molecular class B [metallo-β-lactamases (MBLs)], have emerged on a global scale and represent serious public health challenges, compromising therapeutic choices and complicating patient management.1–3 Genes encoding carbapenemases are associated with mobile genetic elements that allow rapid dissemination in the clinical setting. Therefore, detection and surveillance of carbapenemase-producing organisms have become matters of major importance for the selection of appropriate therapeutic schemes and the implementation of infection control measures.1,3 In this study, we analysed the rates of carbapenem resistance and carbapenemase production among a total of 15 948 isolates of Escherichia coli (n = 10 432) and Klebsiella spp. (n = 5516) consecutively collected during 2007–09, which were evaluated as part of the SENTRY antimicrobial surveillance programme. E. coli and Klebsiella spp. were sampled from 83 medical centres located in the USA, Europe and Latin America (30, 10 and 43 institutions, respectively). These consecutive non-duplicate isolates were cultured from bloodstream, respiratory tract, and skin and skin structure infections. Isolates were tested for antimicrobial susceptibility using the 2009 CLSI broth microdilution method4 and results were interpreted according to the M100-S20-U document (CLSI, 2010).5E. coli ATCC 25922 and Pseudomonas aeruginosa ATCC 27853 were concurrently tested for quality assurance; all results were in the CLSI published range.5 Overall, resistance to imipenem and/or meropenem (MIC values ≥2 mg/L) was observed among 2.0% (323/15 948) of the E. coli (n = 29) and Klebsiella spp. (n = 294; 281 Klebsiella pneumoniae and 13 Klebsiella oxytoca) isolates (Table 1). All 323 isolates resistant to imipenem or meropenem were tested with the modified Hodge test (MHT)6 using imipenem and meropenem discs, and were also screened for the presence of blaIMP, blaVIM, blaKPC,blaSME and blaGES variants as well as for blaIMI, blaNMC-A and blaOXA-48 by multiplex PCRs using custom primers (Table S1, available as Supplementary data at JAC Online). The gene encoding NDM-1 was tested in a separate reaction. Amplicons were sequenced on both strands. Carbapenem resistance and carbapenemase production rates among different groups were compared using the χ2 test. P values <0.05 were considered to be significant. Occurrence of carbapenem-resistant and carbapenemase-producing E. coli and Klebsiella spp. during 2007–09 aP values were calculated by χ2 for trend test; P values <0.0001 were considered statistically significant. OR and respective 95% CI values refer to comparisons between the years 2007 and 2009. bCarbapenem resistance was as defined by CLSI document M100-S20-U.5 cThe vast majority (85.0%) of MBL isolates originated from two Greek medical centres; however, they did not participate in the surveillance programme in 2007 and 2009. Occurrence of carbapenem-resistant and carbapenemase-producing E. coli and Klebsiella spp. during 2007–09 aP values were calculated by χ2 for trend test; P values <0.0001 were considered statistically significant. OR and respective 95% CI values refer to comparisons between the years 2007 and 2009. bCarbapenem resistance was as defined by CLSI document M100-S20-U.5 cThe vast majority (85.0%) of MBL isolates originated from two Greek medical centres; however, they did not participate in the surveillance programme in 2007 and 2009. The rates of carbapenem resistance and carbapenemase production among Klebsiella spp. were higher than those seen among E. coli. Overall, only 29 (0.3%) E. coli strains demonstrated elevated carbapenem MIC values and 16 (0.2%) were carbapenemase producers, whereas among Klebsiella spp. carbapenem resistance and carbapenemase production were 5.3% and 3.8%, respectively (Table 1). Carbapenem resistance rates for all regions combined were stable through the years, varying from 1.8% to 2.4% in 2007 and 2009, respectively {P = 0.0467; odds ratio (OR) 0.76 [95% confidence interval (CI) 0.58–1.01]; Table 1}. Carbapenemase production, detected by MHT and PCR, was observed among 228 (1.4%) isolates and analyses by year demonstrated an increasing trend toward carbapenemase production. In the first 2years, carbapenemase production was 1.2% (2007) and 1.3% (2008), increasing to 1.8% in 2009 [P < 0.0001; OR 0.52 (95% CI 0.37–0.72); Table 1]. Genes encoding OXA-48 (38 isolates) and IMP-type enzymes (2 isolates) were detected in Europe and Latin America. VIM-type enzymes (30 isolates) were observed only in Europe, and KPC serine carbapenemases (158 isolates) were documented in all regions, with a high prevalence in the USA and Israel. One KPC-producing isolate was detected in Latin America (Argentina) in 2007–08; however, in 2009, a total of 10 KPC-2-producing isolates were found in four hospitals located in Brazil and Argentina. OXA-48-producing isolates were detected in Turkey in all studied years and in two Argentinean hospitals in 2007 and 2008. The number of OXA-48-producing isolates in Turkish hospitals increased from 2 and 6 isolates in 2007 and 2008, respectively, to 27 isolates in 2009. In contrast, MBL production rates were stable throughout the 3 years surveyed [P = 0.3836; OR 1.64 (95% CI 0.49–5.74)]. The increase in MBL production observed in 2008 was due to the detection of 17 VIM-like isolates in Greek hospitals (epidemic clone); however, the institutions from that country were not sampled during 2007 or 2009. MBLs were mainly noted in Europe. VIM enzymes (VIM-1 and -2) were found in Spain, Italy, Turkey and Greece. Only one MBL-harbouring isolate was detected in Latin America, an IMP-18-producing K. oxytoca from Mexico. The NDM-1-encoding gene was not detected. Only five strains (all K. pneumoniae) showed repeatedly discrepant results between MHT and PCR. One blaOXA-48- and one blaKPC-2-carrying strain were negative for MHT. Three strains (one from Turkey and two from the USA) were positive for MHT and negative for PCR. Carbapenemase production significantly increased in this systematic evaluation of a contemporary worldwide E. coli and Klebsiella spp. collection, whereas MBL rates were stable over the study period or associated with local epidemic, clonal occurrences. The dissemination of KPC-producing isolates in all geographical regions and of OXA-48 in Turkish hospitals contributed directly to the described escalating resistance trends. Carbapenemase production cannot be inferred from the antimicrobial resistance profile; thus, the dissemination of these enzymes must be closely monitored [molecular and/or phenotypic tests (MHT)] and strategies implemented, as effective surveillance initiatives.7,8 No specific funding was received for this study. All authors are employees of JMI Laboratories, Inc. and this institution has received research and educational grants from Achaogen, Anacor, API, Arpida, Aryx, Astellas, AstraZeneca, Avexa, Bayer, bioMérieux, Becton Dickinson, Cadence, Cempra, Cerexa, Cornerstone Biopharma, Cosmo Technologies, Cubist, Elan, Enanta, GlaxoSmithKline, Johnson & Johnson (Ortho McNeil), LegoChem Biosciences Inc., Meiji Seika Kaisha, Microphage Inc., Migenix, Mpex, Nabriva, Novexel, Novartis, Optimer, Ordway, Paratek, Pfizer (Wyeth), PPD Therapeutics, Premier Research Group, Protez, Shionogi USA, The Medicines Co., Theravance, TREK Diagnostics, Vertex Pharmaceuticals and other corporations. This study was presented at the Fiftieth Interscience Conference on Antimicrobial Agents and Chemotherapy, Boston, MA, 2010 (Poster D-743).
No takes yet. Share an insight, caveat, or question.
Castanheira et al. (2011) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: